Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 2480 • ACR Convergence 2024
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis and Ear, Nose, or Throat Involvement in a Phase 3 Trial
Robert Spiera¹, Robert Lebovics², Sarah Bray³, Rachel E. Gurlin⁴, David Jayne⁵ and Peter Merkel⁶, and ADVOCATE Study Group, ¹Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ²Hackensack Meridian University Health System, Hackensack, NJ, ³Amgen Ltd, Cambridge, United Kingdom, ⁴Amgen Inc., Mountain View, CA, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: In the phase 3 ADVOCATE trial, 45.2% and 42.1% of patients in the avacopan and prednisone taper groups, respectively, had active ear, nose, or…
Abstract Number: 2526 • ACR Convergence 2024
Development of the Hospital Emergency Advocacy & Treatment Kit (HEAT Kit) for Patients with Vasculitis
Sarah Jones¹, Pamela Squires² and Donna McArthur³, ¹Eosinophilic & Rare Disease Cooperative, Tucson, AZ, ²Eosinophilic & Rare Disease Cooperative, Tucson, ³Adjunct professor of nursing, Vanderbilt School of Nursing; Adjunct clinical professor, University of Arizona College of Nursing & Dept. of Neurology, Tucson, AZ
Background/Purpose: All forms of vasculitis are rare with patients frequently experiencing poor or extended care in the hospital and ED settings. The ERDC founder experienced…
Abstract Number: 0680 • ACR Convergence 2023
Risk Factors for Hypogammaglobulinemia and Association with Relapse and Severe Infections in ANCA-Associated Vasculitis: A Retrospective Single-Centre Cohort Study
Johanne LIBERATORE¹, Yann Nguyen², Jerome HADJADJ³, Pascal Cohen⁴, Luc Mouthon⁵, Xavier Puéchal⁶, Loic Guillevin⁷ and Benjamin Terrier⁸, ¹Centre Hospitalier ANGOULEME, Angouleme, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³Cochin Hospital, Paris, France, ⁴CHU Cochin, Paris, France, ⁵Hopital Cochin - Paris University, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁷University Paris Descartes, Paris, France, ⁸Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: B-cell depletion induced by rituximab (RTX) in ANCA-associated vasculitis (AAV) is a risk factor for hypogammaglobulinemia. Aggregating data on the kinetics of gammaglobulin levels…
Abstract Number: 0857 • ACR Convergence 2023
Change in Albuminuria in Patients with ANCA-Associated Vasculitis Treated with Avacopan
Duvuru Geetha¹, Frank Cortazar², alexandre Karras³, Annette Bruchfeld⁴, Huibin Yue⁵, Peter Merkel⁶ and David Jayne⁷, ¹Johns Hopkins University, Baltimore, MD, ²New York Nephrology, Watervliet, NY, ³HEGP - APHP, Paris, France, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Urinary albumin:creatinine ratio (UACR) is an important biomarker of active glomerulonephritis, a common complication of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). In most glomerular…
Abstract Number: 1619 • ACR Convergence 2023
Receipt of Antimicrobial Prophylaxis in U.S. Medicare Beneficiaries Initiating Immunosuppressive Medications for ANCA Vasculitis
Carolyn Thorpe, Ryan Hickson, Sherrie Aspinall, Vimal Derebail, Xinhua Zhao, Joshua Thorpe, Binxin Cao, Alexa Ehlert, Ronald Falk and Susan Hogan, University of North Carolina, Chapel Hill, NC
Background/Purpose: Infections are the leading cause of hospitalization and mortality in patients with ANCA vasculitis (AV). Multiple AV treatment guidelines recommend antimicrobial prophylaxis during treatment…
Abstract Number: 2385 • ACR Convergence 2023
Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis
Jon Idoate¹, Morgane Mourguet¹, Thomas Villeneuve¹, Grégoire Prevot¹, Laurent Guilleminault², Ribes David¹, Stan Faguer¹, Antoine Huart¹, Dominique Chauveau¹, Laurent Alric¹, Martin Michaud¹, Laurent Sailler¹, Sébastien De Almeida Chavez¹, Emmanuelle Mouchon¹, Olivier Lairez¹ and Gregory Pugnet³, ¹CHU Toulouse, Toulouse, France, ²Department of respiratory and allergic diseases, Toulouse University Hospital Center, Toulouse, France, ³CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France
Background/Purpose: The aim of this study was to investigate the risk of major adverse cardiovascular events (MACE) in patients with ANCA-associated vasculitis (AAV). Methods: We…
Abstract Number: 0681 • ACR Convergence 2023
Real-World Outcomes for Remission Induction in Working-Age Adults with Severe Anti-Neutrophil Cytoplasmic Antibody-associated Vasculitis
Itay Marmor¹, Katelin Nickel², Matthew Keller², Guy Hazan³, Kevin Baszis⁴, Anthony French⁵ and Mary Hartman², ¹Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ²Washington University in St. Louis, St. Louis, MO, ³Soroka University Medical Center, Beer Sheva, Israel, ⁴Washington Univ in St. Louis School of Medicine, St. Louis, MO, ⁵Washington University School of Medicine, St. Louis, MO
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), often manifests with life-threatening complications. Cyclophosphamide (CYC) and rituximab…
Abstract Number: 0858 • ACR Convergence 2023
Randomized, Controlled, Double-Blind Trial on the Impact of Rosuvastatin on Sublinical Markers of Atherosclerosis in Patients with ANCA-Associated Vasculitis
Benjamin Terrier¹, Gregory Pugnet², Marie-Emmanuelle Sirieix³, Thomas Quemeneur⁴, Xavier Puéchal⁵, Francois Maurier⁶, Antoine Néel⁷, YGAL BENHAMOU⁸, Bernard Bonnotte⁹, Jean Schmidt¹⁰, Adrien Michon³, Antoine Baudet¹¹, Pierre Charles¹², Fleur Cohen¹³, Claire De Moreuil¹⁴, Emanuelle Dernis¹⁵, Pauline Belenotti¹⁶, Marc Ruivard¹⁷, Olivier Aumaitre¹⁸, Olivier Fain¹⁹, Raphaele Seror²⁰, Cécile-Audrey Durel²¹, Noémie Jourde-Chiche²², Estibaliz Lazaro²³, Gilles Chironi²⁴, Guillaume Armengol²⁵, Jeremy Bellien²⁵, Philippe Ravaud²⁶, Gabriel Baron²⁶ and Loic Guillevin²⁷, ¹Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France, ²CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ³HEGP, Paris, France, ⁴CH Valenciennes, Valenciennes, France, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁶Hôpitaux privés de Metz, Vaux / Frankreich, France, ⁷CHU Nantes, Nantes, France, ⁸rouen university hospital, Rouen, France, ⁹Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ¹⁰CHU Amiens, Amiens, France, ¹¹CH Annecy, Annecy, France, ¹²Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, ¹³Sorbonne Université, Paris, France, ¹⁴CHU de Brest, Brest, France, ¹⁵CH Le Mans, Le Mans, France, ¹⁶CHU Marseille, Marseille, France, ¹⁷CHU Clermont Ferrand, Clermont Ferrand, France, ¹⁸CHU Saint Antoine, Paris, France, ¹⁹Hopital SAINT ANTOINE APHP, Paris, France, ²⁰University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ²¹CHU Lyon, Lyon, France, ²²AP-HM, Marseille, France, ²³Bordeaux Hospital University, Pessac, France, ²⁴Monaco, Monaco, Monaco, ²⁵CHU Rouen, Rouen, France, ²⁶Paris Cité University, Paris, France, ²⁷University Paris Descartes, Paris, France
Background/Purpose: Despite more effective therapeutic strategies in ANCA-associated vasculitis (AAV), there is still a significant risk of morbidity and mortality, mainly due to infection, and…
Abstract Number: 1863 • ACR Convergence 2023
Immune-mediated Hypertrophic Pachymeningitis: Focusing on the Localization and Volume of Thickened Dura Mater Lesion
Yasuhiro Shimojima¹, Junji Ikeda² and Yoshiki Sekijima¹, ¹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ²Department of Medicine (Neurologu and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: Hypertrophic pachymeningitis (HP) is a rare inflammatory neurological disorder characterized by the thickened dura mater with extensive tissue fibrosis and immune-mediated inflammation. Notably, headaches…
Abstract Number: 2386 • ACR Convergence 2023
Impact of ANCA Specificity on Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis
Jon Idoate¹, Morgane Mourguet¹, Ribes David¹, Stan Faguer¹, Antoine Huart¹, Dominique Chauveau¹, Thomas Villeneuve¹, Grégoire Prevot¹, Laurent Guilleminault², Emmanuelle Mouchon¹, Laurent Balardy¹, Laurent Sailler¹, Sébastien De Almeida Chavez¹, Laurent Alric¹, Martin Michaud¹, Olivier Lairez¹ and Gregory Pugnet³, ¹CHU Toulouse, Toulouse, France, ²Department of respiratory and allergic diseases, Toulouse University Hospital Center, Toulouse, France, ³CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France
Background/Purpose: The aim of this study was to investigate the relationship between ANCA specificity and the risk of major adverse cardiovascular events (MACE) in patients…
Abstract Number: 0682 • ACR Convergence 2023
Avacopan in ANCA-associated Vasculitis Received Intensified Induction Therapy with Cyclophosphamide Plus Rituximab – Retrospective Case Serial of 12 Patients
Gunter Assmann¹, Christoph Rittich¹, Frank Neumann², Udo Kellner³, Ryszard Turkiewicz⁴, Joerg Radermacher⁵, Peter Lamprecht⁶ and Björn Tampe⁷, ¹RUB University Hospital Minden - Rheumatology, Minden, Germany, ²Jose Carreras Center Saarland, Homburg, Germany, ³RUB University Hospital Minden - Pathology, Minden, Germany, ⁴RUB University Hospital Minden - Pulmonology, Minden, Germany, ⁵RUB University Hospital Minden - Nephrology, Minden, Germany, ⁶University Hospital Luebeck - Schleswig-Holstein, Luebeck, Germany, ⁷University Clinic department Goettingen - Nephrology, Goettingen, Germany
Background/Purpose: The orally administered C5a receptor inhibitor avacopan is approved for the therapy of ANCA-associated vasculitis (AAV) in combination with rituximab or cyclophosphamide and shows…
Abstract Number: 1152 • ACR Convergence 2023
Relation Between Positive MPO-ANCA Antibodies And: Associated Diseases, Anca-associated Vasculitis Specificty, Severity and Prognosis. Study from a Single University Hospital
Fabricio Benavides¹, Monica Renuncio-García¹, Salma Al Fazazi², clara escagedo Cagigas¹, maria rodriguez Vidriales¹, Vanesa Calvo Río³, Juan Irure-Ventura¹, luis martin penagos⁴, Marcos Lopez-Hoyos⁵ and Ricardo Blanco⁶, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Puerta Del Mar, Cádiz, Spain, ³Valdecilla Hospital, Santander, Spain, ⁴Division of Nephrology, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-DIVAL, Santander, Spain, ⁵Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of pathologies characterized by necrotizing inflammation that mainly affects small and medium-sized vessels. Serum anti-neutrophil cytoplasmic antibodies (ANCA),…
Abstract Number: 2371 • ACR Convergence 2023
Plasma and Urine Cytokine Profiles in Active ANCA-Associated Vasculitis
Salem Almaani¹, Huijuan Song², Stacy Ardoin³, Lynn Fussner² and Brad Rovin², ¹Ohio State University Medical Center, Columbus, OH, ²Ohio State University, Columbus, OH, ³Nationwide Children's Hospital, Columbus, OH
Background/Purpose: ANCA-associated vasculitis (AAV) is a multisystem autoimmune disease that often affects the kidneys. It is unclear why some patients with AAV have kidney involvement…
Abstract Number: 2491 • ACR Convergence 2023
Alignment Between the Novel 2022 ACR/EULAR Classification Criteria for ANCA-associated Vasculitis (AAV), Clinical Diagnosis and Organ Manifestations in a European AAV Cohort
Stefan Krämer¹, Thomas Rauen¹, Kristian Vogt¹, Teresa Anslinger¹, Martin Busch², Tobias Schmitt³, Raoul Bergner⁴, Sebastian Mosberger⁴ and Thomas Neumann⁵, ¹RWTH, University Hospital Aachen, Department of Nephrology and Rheumatology, Aachen, Germany, ²University Hospital Jena, Friedrich-Schiller University, Department of Internal Mediciine III, Jena, Germany, ³University Hospital Jena, Friedrich Schiller University, Department of Nephrology, Jena, Germany, ⁴Municipal Hospital Ludwigshafen, Department of Internal Medicine A, Nephrology and Rheumatology, Ludwigshafen, Germany, ⁵Cantonal Hospital St. Gallen, Department of Rheumatology, St. Gallen, Switzerland
Background/Purpose: In 2022, ACR and EULAR proposed new classification criteria for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) based on a numerical item scoring…
Abstract Number: 0683 • ACR Convergence 2023
Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Duvuru Geetha¹, Frank Cortazar², Annette Bruchfeld³, alexandre Karras⁴, Peter Merkel⁵ and David Jayne⁶, ¹Johns Hopkins University, Baltimore, MD, ²New York Nephrology, Watervliet, NY, ³Karolinska Institutet, Stockholm, Sweden, ⁴HEGP - APHP, Paris, France, ⁵University of Pennsylvania, Philadelphia, PA, ⁶University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the Phase 3 ADVOCATE trial comparing avacopan to a prednisone taper, 81% of patients with ANCA-associated vasculitis (AAV) had renal involvement based on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].